Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects with Active Proliferative Lupus Nephritis - TULIP-LN1

Study identifier:D3461C00007

ClinicalTrials.gov identifier:NCT02547922

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis

Medical condition

Lupus Nephritis

Phase

Phase 2

Healthy volunteers

No

Study drug

Placebo

Sex

All

Actual enrollment

147

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 04 Nov 2015
Primary Completion Date: 26 Nov 2019
Study Completion Date: 18 Jan 2021

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria